A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen - Contacts and Locations

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

This study has been withdrawn prior to recruitment.

Study NCT00319332. Last updated on January 24, 2007. Information provided by GlaxoSmithKline

Please refer to this study by its ClinicalTrials.gov identifier: NCT00319332

Locations


United States, Iowa
	GSK Clinical Trials Call Center
	Iowa City, Iowa, United States, 52242

United States, Missouri
	GSK Clinical Trial Call Center
	St. Louis, Missouri, United States, 63110

United States, New York
	GSK Clinical Trials Call Center
	Buffalo, New York, United States, 14263

United States, North Carolina
	GSK Clinical Trials Call Center
	Charleston, North Carolina, United States, 29425

United States, Oregon
	GSK Clinical Trial Call Center
	Portland, Oregon, United States, 97213

United States, Tennessee
	GSK Clinical Trial Call Center
	Knoxville, Tennessee, United States, 37920

United States, Washington
	GSK Clinical Trial Call Center
	Seattle, Washington, United States, 98109
	GSK Clinical Trials Call Center
	Tacoma, Washington, United States, 98431

Sponsors and Collaborators

GlaxoSmithKline

Investigators


Study Director:	GSK Clinical Trials, MD	GlaxoSmithKline